Four patients with chronic myelogenous leukemia (CML) that was refractory to interferon alpha (two patients) or imatinib mesylate (two patients), and who lacked donors for allogeneic stem cell transplantation, received autotransplants followed by infusions of ex vivo costimulated autologous T cells. At day þ 30 (about 14 days after Tcell infusion), the mean CD4 þ cell count was 481 cells/ll (range 270-834) and the mean CD8 þ count was 516 cells/ll (range 173-1261). One patient had a relative lymphocytosis at 3.5 months after T-cell infusion, with CD4 and CD8 levels of 750 and 1985 cells/ll, respectively. All the four patients had complete cytogenetic remissions early after transplantation, three of whom also became PCR negative for the bcr/abl fusion mRNA. One patient, who had experienced progressive CML while on interferon alpha therapy, became PCRÀ post transplant, and remained in a molecular CR at 3.0 years of follow-up. All the four patients survived at 6, 9, 40, and 44 months post transplant; the patient who remained PCR þ had a cytogenetic and hematologic relapse of CML, but entered a molecular remission on imatinib. Autotransplantation followed by costimulated autologous T cells is feasible for patients with chronic phase CML, who lack allogeneic donors and can be associated with molecular remissions.
immunotherapy; autotransplantation; costimulation; imatinib mesylate Chronic myelogenous leukemia (CML) is a clonal disorder of the hematopoietic stem cell, which uniformly evolves into a lethal acute or 'blastic' phase unless it is eradicated by allogeneic (sibling or matched unrelated) stem cell transplantation. [1] [2] [3] Several lines of evidence indicate that the curative effect of allogeneic marrow transplants is mediated largely by donor-derived antileukemic T cells. 4 This hypothesis has been reinforced by demonstrations that donor-derived T-cell infusions can induce durable cytogenetic and molecular remissions of CML in patients who have disease relapses after initial allogeneic stem cell transplants. [5] [6] [7] [8] However, allogeneic transplantation is associated with substantial treatment-related mortality. The treatment-related mortality is approximately 25% at 1 year for matched-sibling transplants and higher for matchedunrelated transplants. 9 Furthermore, allogeneic stem cell transplantation is not available to patients who lack HLAmatched donors, and may not be suitable for older adults.
High-dose chemotherapy followed by autologous stem cell/marrow rescue has been utilized for CML patients who were ineligible for allogeneic transplants. At least one analysis, adjusted for the duration of chronic phase prior to autografting, suggested a significant survival advantage for autograft recipients, as compared with age-matched recipients of conventional chemotherapy. 10 However, a series of 73 patients who received autografts for advanced-stage CML or interferon-refractory chronic phase disease had a low incidence of complete cytogenetic responses (10 and 14%, respectively), and no apparent survival benefit. 11 When autografting was performed in patients with earlystage, interferon-naı¨ve disease, using mobilized peripheral blood stem cells with a low CML content, eight of 30 patients remained in a complete cytogenetic remission at a median of 20 months, one of whom was PCRÀ for the bcr/ abl fusion mRNA at 44 months of follow-up. 12 As indicated before, CML may be particularly susceptible to immunotherapy, since donor T-cell doses as low as 1 Â 10 7 /kg can reinduce complete and durable cytogenetic remissions in patients with relapsed CML, following HLAmatched allogeneic transplants. 13 The target antigens for this allogeneic T-cell-mediated antileukemic activity may include polymorphic minor histocompatibility antigens (mHA), 14, 15 nonpolymorphic leukemia-restricted antigens such as proteinase 3 peptide, 16 and/or CML-specific peptides derived from the BCR/ABL fusion oncogene product. 17 .
Of particular interest with regard to autografting for CML is that several laboratories have isolated populations of T lymphocytes derived from CML marrow, which can suppress autologous (CML) hematopoietic progenitors. 18, 19 Indeed, treatment of CML cells with GM-CSF, IL-4, and 7TNFa upregulated the surface expression of CD80 and CD86 (frequently absent on CML cells), enabling them to prime T cells for cytotoxic activity against autologous CML targets. [20] [21] [22] Additionally, a variety of MHC-bound peptides relevant to CML and other myeloid leukemias have been isolated from CML blast cells, which may serve as recognition targets for autologous antileukemic T-cell populations. 23 Many of these peptides are derived from dysregulated proteins that may play a role in CML growth or pathogenesis including BCR, c-pim, c-fes, and the GM-CSF-a receptor. Peptides derived from the CML-specific BCR/ABL fusion protein may elicit T-cell responses, but these peptides appear to bind effectively to only selected HLA antigens (A3, A11, B8, DR11).
In an effort to translate these observations regarding the presence of latent autologous CML-reactive T-cell populations to the clinical level, we developed a protocol in which patients with CML were offered autologous transplants, followed by the adoptive transfer of costimulated autologous T cells. This approach was based on the rationale that the T-cell infusions might accelerate immune reconstitution and augment or restore T-cell recognition and targeting of autologous leukemic cells. The objectives of the trial were (1) to determine the feasibility of expanding and infusing autologous T cells from patients with CML and (2) to determine the frequency of hematologic, cytogenetic, and molecular remissions after this approach. Patients with chronic phase CML, who were refractory to either interferon alpha (at the beginning of the study) or imatinib mesylate (since the FDA approval of this agent), were eligible for inclusion. The results to date indicate that T-cell expansion and infusion are feasible and safe for patients with CML, and are associated with the occurrence of molecular responses in several patients.
Patients and methods

Patient eligibility and enrollment
Written and informed consent was obtained from all patients, in accordance with the Institutional Review Board guidelines. Patients were required to have CML based on characteristic clinical and laboratory features, and cytogenetic or molecular evidence for the bcr/abl gene rearrangement. Patients had to be ineligible for allogeneic stem cell transplantation from a histocompatible sibling or unrelated donor. While patients could be in chronic or accelerated phase at the time of transplantation, first or second chronic phase was required prior to stem cell harvesting. Adequate renal, cardiac, pulmonary, and hepatic functions were required, and patients could not have active infections or HIV seropositivity. In addition, patients were expected to have had prior therapeutic trials of either interferon alpha or, more recently, imatinib mesylate, and to have demonstrated unsatisfactory responses, disease progression, or poor tolerance. A total of eight patients have been enrolled on the protocol: one patient progressed to blastic phase before any study procedures could be performed and was taken off study; one patient who was in the second chronic phase was ultimately found to have a histocompatible sibling, and proceeded to allotransplantation; two patients had complete cytogenetic responses to interferon alpha (one patient) or imatinib mesylate (one patient), and were enrolled for lymphocyte and stem cell collection and storage only; one patient who had lymphocytes and stem cells collected after obtaining a complete cytogenetic response to imatinib mesylate later had progression and proceeded to autotransplantation; three patients had progression of CML while on interferon alpha (two patients) or imatinib mesylate (one patient). The latter four patients formed the basis for this report.
Steady-state lymphocyte collection
Patients first underwent a steady-state leukapheresis using an automated cell separator (Cobe Spectra cell collector or equivalent). Approximately 20-30 l of blood was processed through a large bore catheter, to obtain about 1.5 Â 10 8 mononuclear cells per kg body weight. These cells were cryopreserved for later expansion in the anti-CD3/anti-CD28 culture system.
Mobilization chemotherapy and stem cell processing
After lymphocyte collection, patients received dose-intensive chemotherapy for CML suppression and autologous stem cell mobilization. On day 1, patients received cyclophosphamide at a dose of 4.5 g/m 2 over 12 h, along with MESNA (4.5 gms/m 2 ) over 18 h as a urothelial protectant. On day 2, patients received etoposide at a dose of 2.0 g/m 2 over 4-6 h. On days 3 and 4, patients received GM-CSF at a dose of 10 mg/kg (rounded to the nearest 250 mg), and then, beginning on day 5, patients received G-CSF at a dose of 16 mg/kg. The selection of dose-intensive cyclophosphamide and etoposide for this phase of treatment was based on significant activity for this drug combination in advanced myeloid leukemia, and our institutional experience, which demonstrated favorable CD34 þ progenitor cell mobilization kinetics after this regimen (Brown et al 24 , unpublished observations). Patients received antibiotic prophylaxis during the period of marrow aplasia, consisting of levofloxacin/famciclovir/ fluconazole. Leukapheresis commenced when the CD34 þ progenitor cell concentration in the peripheral blood was X20 CD34 þ cells/ml. For patients whose cells were collected for storage during a period of favorable marrow response to interferon alpha or imatinib mesylate, only sequential GM-CSF and G-CSF were employed for mobilization. The CD34 þ cell collection target was X6 Â 10 6 CD34 þ progenitors/kg body weight. Initially, X1 Â 10 6 CD34 þ cells/kg were cryopreserved as a back-up for graft failure, while about 5 Â 10 6 CD34 þ cells/kg were subjected to positive CD34 immunoselection, using the Baxter Isolex 300I Magnetic Cell Separation System (Baxter Oncology, Deerfield, IL, USA), in accordance with the manufacturer's instructions. Later, the protocol was amended to eliminate the immunoselection step. Three of the four patients in this report received CD34 þ selected products, one of whom also received a nonselected backup product for delayed engraftment (UN-6); one patient was transplanted after immunoselection was discontinued (UN-7). Although it was hoped that the mobilization procedure would yield stem cell products with low CML contents, this was not essential for proceeding with the protocol. However, the two patients (UN-1, UN-2) whose stem cell products were tested for CML contamination were found to be 95 and 92% normal by FISH analysis, despite having about 85% CML cells in the marrow prior to mobilization.
High-dose therapy
High-dose therapy consisted of the gemcitabine/BCNU/ melphalan (GBM) regimen. 25 Patients received gemcitabine at a dose of 1.0 g/m 2 over 100 min on day À5 as an outpatient. On day À2, patients were admitted to the hospital and received BCNU at a dose of 300 mg/m 2 over 2 h, followed 6 h later by a second dose of gemcitabine. On day À1, patients received melphalan at a dose of 140 mg/m 2 over 20 min. Autologous stem cells were infused on day 0. GM-CSF was used primarily for post transplant growth factor support at a dose of 250 mg/m 2 starting on day þ 1. However, G-CSF could be substituted for clinically significant side effects attributable to GM-CSF. Standard transfusional support was employed using irradiated blood products.
Ex vivo costimulation and expansion of T-lymphocytes
T cells were cultured, as specified, in an FDA-approved investigational new drug application. Around day 0 of the autotransplantation phase, the cryopreserved mononuclear cells were thawed and washed three times in PBS with 1% human serum albumin. If not performed at the time of initial cryopreservation, the mononuclear cells were monocyte-depleted using magnetic beads in a closed system. The cells were then seeded into gas-permeable flasks (Baxter Oncology, Deerfield, IL, USA) containing X-VIVO s supplemented with 5% pooled AB serum. Magnetic beads with immobilized anti-CD3 (OKT3) and anti-CD28 (9.3) monoclonal antibodies were added at a 3:1 bead:CD3 þ cell ratio, and the cultures were maintained for up to 14 days prior to harvest and preparation for infusion, as described. 26, 27 The cells were counted daily and fresh medium was added to maintain the cells at a density of 0.75-2 Â 10 6 /ml. IL-2 at 100 IU/ml was added, if necessary, to optimize the cell growth, but was not used on a routine basis. After completion of cell culture, the magnetic beads were removed using a Baxter Fenwal Maxsep s magnetic cell separation device. 27 After removal of the beads, the cells were washed, concentrated and resuspended in 100-250 ml of Plasmalyte A containing 1% human serum albumin, using the Baxter Fenwal Harvester System.
Reinfusion of ex vivo expanded T cells
Before release, all the harvested products were required to meet the criteria for cell viability (X70%), sterility (negative cultures for bacteria and fungi, negative endotoxin assay), and bead contamination (o100 beads/3 Â 10 6 cells). The target CD3 þ cell dose for this protocol was 5-10 Â 10 9 . The harvested cells were transported by courier from the cell production facility to the patient and infused on the same day. The cells were infused over 20-60 min without a leukocyte filter, on day 14 after stem cell infusion. Patients were routinely premedicated with acetaminophen and diphenhydramine. Meperidol was used for the treatment of chills, and corticosteroids were kept at the bedside but not routinely used.
Post transplant evaluations and treatments
Patients were scheduled to have marrow aspirations at 1, 2, 3, 6, 9, and 12 months post transplant and every 3-6 months thereafter. Specimens were tested for residual CML by G-banding (20-30 cells analyzed) and FISH analysis (200 cells analyzed), using standard procedures. In addition, total RNA was extracted from the marrow, and sometimes peripheral blood samples for cDNA derivation and nested PCR analysis, to test for the evidence of bcr/abl fusion mRNA. Briefly, total cellular RNA was extracted and 1 mg of RNA was subjected to reverse transcription using random hexamers to generate cDNA. Subsequently, the cDNA was PCR amplified with an ABL exon 2 primer and a primer homologous with exon 2 of the m-BCR region of the BCR gene (which corresponds to exon 13 of the wildtype BCR gene). The products from this reaction were subsequently reamplified using nested primers, internal to those used for the first RT-PCR reaction. The amplification products were subjected to gel electrophoresis and visualized by ethidium bromide staining. As a positive control for the integrity of the RNA, RNA was also subjected to RT-PCR using primers for the beta-2-microglobulin gene. Peripheral blood samples were also obtained for CD4/CD8 lymphocyte enumeration and for immune response assays. At about 3 months post transplant, patients were started on maintenance interferon alpha at a dose of 2.5-5.0 million units, subcutaneously, three times per week. In addition, imatinib mesylate could be restarted at about 3 months post transplant for maintenance treatment, at the discretion of the treating physician.
Results
Patient characteristics
A total of eight patients were enrolled in the study between May 1999 and October 2002. The advent of imatinib mesylate therapy for CML management slowed patient accrual and, therefore, the protocol was amended to include patients who were resistant to imatinib mesylate therapy. Two patients (UN-3 and UN-4) were enrolled while in second chronic phase, and both reverted to blastic phase (one myeloid, one lymphoid) shortly after completion of autologous stem cell mobilization (UN-3) or shortly before mobilization chemotherapy was scheduled to begin (UN-4). These patients were consequently taken off from study; patient UN-3 ultimately received an allogeneic stem transplant from a HLA-matched sibling who was unavailable at the time of study enrollment. Two patients (UN-5, UN-8) had complete cytogenetic responses to imatinib mesylate and interferon alpha, respectively, and went on study for T-cell collection and autologous stem cell mobilization and storage only. The remaining four patients (UN-1, UN-2, UN-6 , and UN-7) received autologous stem cell transplants and post transplant infusions of costimulated T cells. Two patients (UN-1 and UN-2) were transplanted after exhibiting progressive disease following treatment with interferon alpha for 1.5 and 2.5 years, respectively. Two patients (UN-6 and UN-7) were transplanted after exhibiting progressive disease following treatment with imatinib mesylate for 3.0 and 1.0 years, respectively. Steady-state T cells and hematopoietic growth factor-mobilized stem cells were collected from patient UN-6 during a period of complete cytogenetic remission from imatinib mesylate, while T cells and stem cells were collected from patient UN-7 during a period of disease progression. The characteristics of these four patients are shown in Table 1 .
Cell collections, stem cell transplantation, and T-cell expansion
After mobilization chemotherapy using dose-intensive cyclophosphamide and etoposide followed by sequential GM-CSF and G-CSF, a median of 23 Â 10 6 CD34 þ progenitors (per kg body weight) were collected (range 8.2-32.7) during a median of 1 day of leukapheresis (range 1-2). Aliquots of the stem products from two patients (UN-1 and UN-2) were tested for CML contamination by FISH analysis prior to CD34 þ immunoselection, and these products were 95 and 92% normal, respectively. All patients had complete (UN-1, UN-2, UN-6) or major (UN-7) cytogenetic responses in the marrow after stem cell mobilization, although UN-1 had progression of disease between mobilization and transplantation such that the marrow contained 95% CML cells at the time of the autotransplant procedure. Positive CD34 immunoselection was performed on the stem cell products of three patients (UN-1, UN-2, and UN-6).
High-dose therapy was generally well tolerated by all four patients. Expected grade 4 hematologic toxicities were observed. However, patient UN-6 developed a capillary leak reaction following completion of the high-dose chemotherapy and prior to stem cell infusion, which caused dyspnea, pulmonary infiltrates, and peripheral edema. This reaction responded to glucocorticoid therapy. The three patients whose stem cell products were immunoselected received a median of 7.0 Â 10 6 CD34 þ progenitor cells (per kg body weight) (range 2.3-11.03), while patient UN-7 received a total of 8.7 Â 10 6 unselected CD34 þ progenitors (per kg body weight). In addition, on day 26 after stem cell transplantation, patient UN-6 received 2.7 Â 10 6 unselected CD34 þ progenitors (per kg body weight) as a backup infusion for delayed engraftment. For the four patients, the median time to reach an absolute neutrophil count of 500/ml was 14 days (range 12-16 days), while the median time to reach an unsupported platelet count of 50 000/ml was 30 days (range 13-68 days).
All the four patients received ex vivo costimulated and expanded T cells about 14 days after autologous stem cell transplantation. These cells were placed into culture with the anti-CD3/anti-CD28 immunomagnetic beads around day 0 of transplantation, and expanded for 10-14 days. There were no culture failures. Using the lowest number of cells in culture as a baseline, the cells were expanded 9-16-fold. A median of 6.7 Â 10 9 CD3 þ cells (range 2.67-10.7) were infused, containing a mean of 71% CD3 þ /CD4 þ cells (range 46-86%). Interleukin 2 was added to the cultures for patients UN-6 and UN-7, at a concentration of 100 IU/ml for the duration of the cultures.
Clinical toxicity from T-cell infusions
All patients received acetaminophen and diphenhydramine prior to T-cell infusions. Early toxicities from T-cell infusions included chills and low-grade fevers, which responded readily to meperidol. There were no grade 3 or 4 immediate toxicities. Later adverse events included grade 1 rashes in two patients (UN-6, UN-7). These pruritic rashes were mainly distributed over the face, shoulders, and upper extremities, and occurred 22 days and 14 days after the T-cell infusions. Skin biopsies were performed in both patients, and revealed a spongiotic dermatitis with a mild exocytosis of CD3 þ lymphocytes, suggestive of a drug eruption for patient UN-6. For patient UN-7, the biopsy revealed a moderate superficial and deep perivascular lymphocytic infiltrate with mild eosinophilia. The rash of patient UN-6 resolved rapidly over several days without specific therapy, while the rash of patient UN-7 resolved more slowly over several weeks with topical emollients and antibiotics. These events were considered to be possibly related to the T-cell infusions, since they were temporally related. In addition, patient UN-1 developed episodes of mental confusion at 9 months after T-cell infusion. The characteristics for the four patients who were transplanted on study are shown. WBC is the white blood count (per ml) at diagnosis; duration is the time interval between diagnosis and study enrollment; prior treatment is detailed along with the maximum response in parentheses; status is the status of disease at the time of enrollment, noting that UN-7 had peripheral basophilia; % CML is the percentage of CML cells in the marrow by G-banding or FISH at the time of enrollment. None of the patients had additional cytogenetic abnormalities, beyond the Philadelphia chromosome (UN-1, UN-6, UN-7) or its molecular equivalent (UN-2) at the time of enrollment.
A lumbar puncture and MRI scan of the brain revealed no abnormalities. This event was considered unlikely to be related to the T-cell infusion, since the timing was unusual and other factors including medications were thought to be responsible. The syndrome resolved completely. There were no grade 3 or 4 late toxicities.
Lymphocyte recovery
The pace of lymphocyte recovery after T-cell infusion was rapid and robust for all the four patients. The mean CD3 þ /CD4 þ count at day 30 after transplantation (about day 14 after T-cell infusion) was 481 cells/ml (range 270-834), while the mean CD3 þ /CD8 þ count at day 30 was 516 cells/ml (range 173-1261). In addition, patient UN-2 developed a relative lymphocytosis at 4 months post transplant (3.5 months post T-cell infusion), at which time the CD3 þ /CD4 þ count was 750 cells/ml and the CD3 þ / CD8 þ count was 1985 cells/ml. Figure 1a and b shows the patterns of CD3 þ /CD4 þ and CD3 þ /CD8 þ cell recovery for the four patients.
Responses and survival
All the four patients had complete hematological and cytogenetic responses early (day 30) after autotransplantation. Three patients (UN-2, UN-6, UN-7) remained in complete cytogenetic remission by FISH and/or G-banding at 36, 4, and 3 months of follow-up, respectively. In addition, these same three patients (UN-2, UN-6, UN-7) had at least transient molecular responses with no evidence for bcr/abl fusion mRNA by nested PCR analysis of peripheral blood, marrow or both. Indeed, patient UN-2, who first became transiently PCR negative at 9 months post transplantation, later turned PCR þ at 1.25 years and then became PCR negative in the marrow again at 1.75 years of follow-up. This patient remained in molecular remission by PCR analysis of the marrow at 3 years of follow-up (see Figure 2 ). In addition, patient UN-6 was PCR negative in the peripheral blood at 3 months post transplant, and patient UN-7 was PCR negative in the marrow and blood at 2 months of follow-up. Figure 2 shows the results of PCR analysis for patients UN-2, UN-6, and UN-7. With longer follow-up and as shown partly in Figure 2 , patients UN-6 and UN-7 had progression of CML in the marrow and/or blood. After reinstitution of imatinib mesylate, to which both patients had been resistant prior to transplant, cytogenetic stabilization ensued. At the last follow-up (9 months (UN-6) and 6 months (UN-7) post transplant), both patients remained in complete hematologic remission. In addition, patient UN-6 had a major cytogenetic remission (85% normal by FISH in the marrow; 91% normal by FISH in the blood) and patient UN-7 also had a major cytogenetic remission (65% normal by G-banding in the marrow), and while on maintenance low-dose interferon (5 million units thrice weekly) and imatinib mesylate (400-800 mg/day). Patient UN-1 remained PCR þ throughout follow-up, and also developed a cytogenetic relapse at 4 months post transplant while on interferon alpha maintenance therapy. At 1 year, a marrow examination showed only 36% normal cells by G banding. This patient was later started on imatinib mesylate therapy and had a complete cytogenetic and molecular response. The four patients were alive and well at 6, 9, 40, and 44 months following autotransplantation, with a performance status of 0-1.
Discussion
This report is the first to examine the feasibility of expanding and infusing autologous T cells in patients who were autografted for CML. Autotransplantation has been performed for patients with CML who lacked suitable allogeneic donors, on the premise that cytoreduction from high-dose therapy might postpone evolution to the blastic phase. In addition, a variable proportion of autograft recipients develop at least transient major or even complete cytogenetic responses, depending on the stage of disease and amount of prior treatment. However, cytogenetic and hematologic relapses occur in the vast majority of autograft recipients, due in part to the lack of the 'graft-versusleukemia' effect seen in the allogeneic transplant setting. Recent studies have suggested that patients with CML may carry T cells, which are capable of CML recognition and cytotoxicity, when stimulated ex vivo with IL-2 or CMLderived DCs. [18] [19] [20] [21] [22] These T cells may be inactivated in vivo due to counter-regulatory signals from leukemic cells which lack key costimulatory molecules such as B7.1 and B7.2 (CD80 and CD86). One potential strategy for restoring antileukemic cell recognition and activity could be to remove autologous T cells from this counter-regulatory environment, and to activate and expand the T cells ex vivo through costimulation from 'artificial' antigen-presenting cells. In this study, the 'artificial' antigen-presenting cells were anti-CD3/anti-CD28-conjugated immunomagnetic beads. Following ex vivo costimulation, the autologous T cells were infused at a time of minimal residual disease when the immunoregulatory environment might be more conducive to the development of antileukemic immune responses. While it is possible that this culture system might nonspecifically activate and expand 'anergic' CML-reactive T cells, specific expansion of CML-reactive T-cell clones will likely require the introduction of CML antigens (eg BCR/ABL peptides or CML-derived DCs) either ex vivo or in vivo as vaccines. This study provides a platform on which to develop such 'combined' immunotherapeutic strategies.
One objective of this study was to determine the feasibility of expanding autologous T cells, which were isolated from patients with CML, and the safety of infusing them during the post transplant period. T cells from the four patients expanded nine-to 16-fold in the immunomagnetic bead culture system, despite extensive prior therapy with interferon alpha (three patients) and/or imatinib mesylate (two patients). Conceivably, T-cell growth in this system could be adversely affected by previous cytotoxic therapy, as has been observed in a similar study of patients with relapsed lymphoma. 28 In addition, the infusions of costimulated T cells were well tolerated: no grade 3 or 4 early nor late toxicities attributable to the T cells were observed. One patient in a similar study for relapsed lymphoma developed a neurologic syndrome characterized by hemiparesis, brainstem hemorrhages, and an atypical lymphoid infiltrate of the choroid plexus. This event was considered to be possibly related to the T-cell infusion, and the patient made a full recovery.
Lymphocyte recovery (and in particular CD3 þ /CD4 þ recovery) was rapid and robust, an unusual finding after autotransplantation using primarily CD34 þ selected stem cells. 29, 30 This same observation was made in an earlier dose-finding study, in which the authors also found a correlation between the dose of infused T cells and the absolute lymphocyte count on day þ 30. 28 An ongoing randomized study of T-cell immunotherapy following autotransplantation for myeloma should help to definitively answer whether post transplant lymphocyte recovery is accelerated by the adoptive transfer of costimulated T cells. The mechanism of accelerated lymphocyte recovery is unclear, whether due to proliferation of the infused cells or induction of endogenous lymphocyte growth, and the clinical benefit, if any, remains to be determined. However, earlier studies suggested that early lymphocyte recovery is associated with superior clinical outcomes after autotransplantation for a variety of hematologic malignancies. [31] [32] [33] We also observed one instance of a delayed relative lymphocytosis, at about 3.5 months after T-cell infusion. This patient (UN-2) also became PCR negative for CML 5 months after this event. Previous studies have described a similar syndrome of delayed lymphocytosis after adoptive T-cell transfers which correlated with tumor regressions. 28, 34 A second objective of this study was to determine the frequency of hematologic, cytogenetic, and molecular responses after autotransplantation, followed by adoptive T-cell transfer. All the four patients had complete hematologic and complete cytogenetic responses early after transplantation. An unexpected finding in this group of patients with interferon or imatinib mesylate-refractory CML was that three of the four patients had at least transient molecular remissions as well. PCR negativity for the bcr/abl fusion transcript is very unusual after autotransplantation for CML. One of 30 patients in a study of previously untreated patients (except for hydroxyurea) had a molecular remission at 44 months of follow-up. 12 In another study, one patient (of 17) who received roquinimex as post transplant immunotherapy was PCR negative at 33 months of follow-up. 35 Although two of the molecular responses seen in our study occurred early after T-cell infusion and could have been due to the transplant alone, the response which occurred in patient UN-2 was delayed in onset and has been durable features which are more typical of an 'antileukemic' immune-mediated response. Although low-dose interferon alpha was utilized for maintenance therapy, in this patient, the disease was previously refractory to this agent. However, it must be acknowledged that this single-patient clinical response may have been due to the transplant regimen and the post transplant interferon therapy, since it is conceivable that the transplant procedure may have restored the sensitivity of the CML to interferon alpha. Immunoassays were performed on samples from another patient (UN-1), who did not have a durable cytogenetic response. Although measurable T-cell responses against autologous marrow DCs were detected (data not shown), we were unable to demonstrate the specificity for CML-DCs nor a change in the level of response in relation to the treatment phase. These studies were partly hampered by the lack of adequate numbers of stimulator and responder cells, as well as uncertainty about the relevant T-cell targets. In an ongoing study of autotransplantation for myeloma, these problems have been rectified by including post transplant 'miniapheresis' procedures to ensure the availability of adequate numbers of T cells, and by including a T-cell-dependent vaccine, a known target antigen, in order to provide a more reliable 'readout' of immune responses.
Another important conclusion from the present study was that autotransplants and ex vivo T-cell expansion could be successfully performed after prolonged prior therapy with imatinib mesylate. This agent has altered the treatment paradigm for CML as a result of the high rate of hematologic and cytogenetic responses. 36, 37 Indeed, imatinib mesylate has become the frontline treatment for chronic phase CML, causing higher risk transplant approaches to be postponed if not abandoned. Nonetheless, acquired resistance to imatinib mesylate does sometimes occur and backup treatments should be developed. In our study, two patients received autotransplants after developing relapse or progression of CML following 3 years (UN-6) or 1 year (UN-7) of imatinib mesylate treatment. For one patient (UN-6), T cells and stem cells were collected about 1.5 years after imatinib mesylate treatment, at a time of complete cytogenetic remission, while T cells and stem cells from the second patient (UN-7) were collected at a time of active disease. T cells from these two patients were expanded 16-and 11-fold, respectively, during costimulation, and post transplant hematopoietic reconstitution was rapid and complete (although patient UN-6 received a backup infusion of unselected stem cells). Both patients had complete cytogenetic and molecular responses early after transplantation. Furthermore, both patients UN-6 and UN-7 seemed to have cytogenetic responses or stabilization following the readdition of imatinib mesylate to maintenance interferon. Whether this phenomenon reflected the re-emergence of 'imatinib mesylate-sensitive' clones or a cooperative effect between costimulated T cells, low-dose interferon and imatinib mesylate, is unknown. The experience with patient UN-1, who obtained a molecular remission while receiving imatinib mesylate for post transplant relapse of CML, also emphasizes that imatinib mesylate can be highly effective when administered after failure of autotransplantation. A larger experience will be needed to determine whether the frequency of molecular responses is higher for patients who receive imatinib mesylate after autografting, as compared with imatinib mesylate alone.
Hopefully, the present study and future studies will provide a foundation on which to develop effective immunotherapeutic strategies for patients with a variety of hematological malignancies, for whom autotransplantation is currently a valuable but imperfect treatment.
